anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Stillbirth is a silent tragedy that shatters the lives of women, families, and nations. Though affecting over 2 million infants globally in 2019, it remains overlooked, with no specific targets dedicated to its reduction in the sustainable development goals. Insufficient knowledge regarding the primary risk factors contributing to stillbirths hinders efforts to reduce its occurrence. Driven by this urgency, this study focused on identifying the determinants of stillbirth among women giving birth in hospitals across North Wollo Zone, Northeast Ethiopia.
METHODOLOGY: This study employed an institution-based unmatched case-control design, involving a randomly selected sample of 412 women (103 cases and 309 controls) who gave birth in hospitals of North Wollo Zone. Data were collected using a structured data extraction checklist. Data entry was conducted using Epi-data version 3.1, and analysis was performed using SPSS version 25.0. Employing a multivariable logistic regression model, we identified independent predictors of stillbirth. The level of statistical significance was declared at a p-value < 0.05.
RESULTS: Our analysis revealed several critical factors associated with an increased risk of stillbirth. Women who experienced premature rupture of membranes (AOR = 5.53, 95% CI: 2.33-9.94), induced labor (AOR = 2.24, 95% CI: 1.24-4.07), prolonged labor exceeding 24 hours (AOR = 3.80, 95% CI: 1.94-7.45), absence of partograph monitoring during labor (AOR = 2.45, 95% CI: 1.41-4.26) were all significantly associated with increased risk of stillbirth. Preterm birth (AOR = 3.46, 95% CI: 1.87-6.39), post-term birth (AOR = 3.47, 95% CI: 1.35-8.91), and carrying a female fetus (AOR = 1.81, 95% CI: 1.02-3.22) were at a higher risk of stillbirth.
CONCLUSION: These findings highlight the importance of early intervention and close monitoring for women experiencing premature rupture of membranes, prolonged labor, or induced labor. Additionally, consistent partograph use and enhanced prenatal care for pregnancies at risk of preterm or post-term birth could potentially contribute to reducing stillbirth rates and improving maternal and neonatal outcomes. Further research is needed to investigate the underlying mechanisms behind the observed association between fetal sex and stillbirth risk.
Curcumin is a water insoluble component of turmeric, the yellow spice from the rhizome of the herb  Curcuma longa  L. (Zingiberaceae), that is widely used as a food flavoring and coloring agent. Curcumin has a long history of medicinal use for a wide variety of medical conditions. The World Health Organization approved its use as non-toxic food additive and a potentially safe drug. Oral administration is well tolerated, but bioavailability is very low. Less than 1% of the curcumin makes its way to the bloodstream, where the liver rapidly destroys most of it. A suitable protein carrier system covalently linked to curcumin with conserved natural curcumin functional chemical groups, of free water solubility, easy digestibility, free intestinal absorption, long serum half-life should help getting the utmost possible beneficial effects of this historical, albeit promising treatment for several acute and chronic illnesses. Additionally, the protein-curcumun conjugate could be used as health food additive and a natural food colorant. Accordingly, based on the successful application of our previous "Patent Pending PCT/EG2008/000044" filed on 20/11/2008 under "Long Acting Conserved Natural Functional Groups Curcumin", the need for the present development looked urgent through the use of several other protein carrier systems for curcumin. The successful clinical application of a globular carrier protein system for curcumin has been internationally published in the Journal of International Society for Sexual Medicine and is available online since Oct. 19 2009 12:02PM, under "Novel Water-soluble Curcumin Derivative Mediating Erectile Signaling".
PROBLEM TO BE SOLVED: To provide the subject cosmetic capable of easily improving an unstable state of feelings by including glycyrrhizic acid. SOLUTION: This cosmetic is obtained by including glycyrrhizic acid and/or physiologically permissible salts in the ratio of pref. 0.001 to 1 wt.% and, pref., adding 0.001 to 1 wt.% of γ-oryzanol. It is allowed to optionally include, in addition to the above components, optional components usable in general cosmetics, e.g. liquid paraffin, hydrocarbon e.g. microcrystalline wax, ester e.g. jojoba oil, higher alcohol e.g. cetanol, anionic surfactant, cationic surfactant, amphoteric surfactant, palyhydric alcohol or thickening agent. It is the most preferable to add the essence of malt in the ratio of pref. 0.01 to 1%.
A stomach-targeted oral macromolecular carrier and a preparation method therefor. The oral macromolecular carrier comprises continuous a drug-loaded microneedle assembly and a fuel-loaded tail wing assembly. The microneedle assembly is a conical needle tip, and the tail wing assembly is connected to the conical bottom surface of the microneedle assembly and protrudes outwardly from the conical bottom surface, thereby avoiding perforation when the carrier breaks through the gastric mucosal barrier. The microneedle assembly is formed by curing a hydrogel pre-solution mixed with a macromolecular drug. The tail wing assembly is formed by curing a hydrogel pre-solution mixed with a fuel substance. The carrier has the advantages of simple preparation process, low cost, high universality and the like.
This group will transfer primary care to the SUMMIT team, which consists of: 1 primary care provider, 1 clinical nurse, 1 team manager, 2 care-coordinators, 2 behavioralists, 1 clinical pharmacist. This interdisciplinary team will have reduced patient panel load and increased flexibility in time and scheduling in order to foster trust and continuity with the patient with a goal of decreasing treatment burden and increasing patient capacity. Specific activities that participants will receive include: 1) comprehensive initial intake and care plan development that incorporates patient goal setting; 2) flexible scheduling of appointments with outreach; 3) transitional care coordination; 4) built-in behavioural counselling and case management; 5) regular review of care plan by team members.
Depakote (divalproex sodium) is a valproate and is indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgment, aggressiveness, and possible hostility. 

The efficacy of Depakote was established in 3-week trials with patients meeting DSM-III-R criteria for bipolar disorder who were hospitalized for acute mania [see Clinical Studies (14.1)]. 

The safety and effectiveness of Depakote for long-term use in mania, i.e., more than 3 weeks, has not been demonstrated in controlled clinical trials. Therefore, healthcare providers who elect to use Depakote for extended periods should continually reevaluate the long-term usefulness of the drug for the individual patient.
Anticoagulants have long been fundamental in preventing and treating thromboembolic disorders, with a recent shift of focus towards direct oral anticoagulants, thanks to their ease of use, efficacy, and safety. Despite these advancements, bleeding complications remain a major concern with any anticoagulant, highlighting the need for safer drugs. Factor XI (FXI) inhibitors have emerged as promising agents in this regard, offering a novel approach by targeting upstream factors in the coagulation system. Phase II trials have shown encouraging outcomes, indicating a reduced bleeding risk compared to that associated with traditional anticoagulants, particularly in the context of cardiovascular disease management when combined with antiplatelet therapy. However, the variability in findings and limited efficacy data call for a cautious interpretation pending insights from phase III trials. These trials are essential for validating the potential of FXI inhibitors to balance bleeding risk reduction and maintain anticoagulant efficacy. This review explores the pharmacology, potential indications, clinical data, and future directions of FXI inhibitors, providing a perspective on their evolving role in anticoagulant therapy. It also provides a detailed analysis of data from published clinical trials on FXI inhibitors in various indications. Preliminary data from ongoing trials are also outlined. As the field moves forward, a cautiously optimistic outlook can be expected, focusing on comprehensive data from phase III trials to define the role of FXI inhibitors in various clinical scenarios.
Ciprofloxacin tablets should be administered orally as described in the Dosage Guidelines table. An increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues, has been observed (see ADVERSE REACTIONS and CLINICAL STUDIES).

Dosing and initial route of therapy (i.e., I.V. or oral) for complicated urinary tract infection or pyelonephritis should be determined by the severity of the infection. In the clinical trial, pediatric patients with moderate to severe infection were initiated on 6 to 10 mg/kg I.V. every 8 hours and allowed to switch to oral therapy (10 to 20 mg/kg every 12 hours), at the discretion of the physician.

* The total duration of therapy for complicated urinary tract infection and pyelonephritis in the clinical trial was determined by the physician. The mean duration of treatment was 11 days (range 10 to 21 days).

** Drug administration should begin as soon as possible after suspected or confirmed exposure to Bacillus anthracis spores. This indication is based on a surrogate endpoint, ciprofloxacin serum concentrations achieved in humans, reasonably likely to predict clinical benefit.5 For a discussion of ciprofloxacin serum concentrations in various human populations, see INHALATIONAL ANTHRAX – ADDITIONAL INFORMATION.

Pediatric patients with moderate to severe renal insufficiency were excluded from the clinical trial of complicated urinary tract infection and pyelonephritis. No information is available on dosing adjustments necessary for pediatric patients with moderate to severe renal insufficiency (i.e., creatinine clearance of < 50 mL/min/1.73m2).
Patients in the control group will receive standard treatment established for eCPR patients on our ICU. This standard treatment includes, among others, targeted temperature management (TTM) for the first 72 hours. For the use of ECLS as well as TTM we are following well established standard operating procedures (control: standard eCPR (va-ECMO)).
<P>PROBLEM TO BE SOLVED: To obtain a cough treatment composition containing theobromine.  <P>SOLUTION: The cough treatment composition comprises 80-99 wt.% based on the total weight of the composition of a theobromine compound or its physiologically acceptable salt and 1-20 wt.% of a lubricant. A dose per time of the cough treatment composition is 300-500mg calculated as a theobromine component of the theobromine compound or its physiologically acceptable salt. The cough treatment composition is useful for treating coughs caused by asthma, postnasal discharge or gastro-esophageal reflux. The lubricant is talc, magnesium stearate or their mixtures. The cough treatment composition is preferably a capsule formulation. The cough treatment composition has excellent effect of relieving cough symptoms induced by cause diseases such as asthma, postnasal discharge or gastro-esophageal reflux. Having reduced abnormal reaction, the cough treatment composition is safely taken.  <P>COPYRIGHT: (C)2008,JPO&INPIT
FIELD: chemistry, biochemistry. ^ SUBSTANCE: claimed invention relates to immunology and biotechnology. Claimed are versions of neutralising antibodies or their functional analogues against human NOGO-A, each of which is characterised by set of specific CDR. Described is pharmaceutical composition for human NOGO-A neutralisation. Described are versions of application of antibodies or their functional analogues in production of medication for treatment and/or prevention of neurological diseases/ disorders. Described is method of axon growth stimulation using antibodies of invention. ^ EFFECT: ensuring neutralising antibodies with high affinity to human NOGO-A, with KD of 10-9 M, which can be further applied in medicine for activation of neurite growth. ^ 17 cl, 45 dwg, 14 tbl, 18 ex
BACKGROUND/AIM: This study sought to explore the life situation of male patients at a critical stage after surgery for esophageal cancer and to enlighten their need for support from healthcare providers during their return to daily life.
PATIENTS AND METHODS: In-depth and semi-structured interviews were conducted with six patients following surgery for esophageal cancer. The interview data were analyzed via inductive thematic analysis.
RESULTS: The patient quality of life was seriously impacted by their remaining symptoms six to eight months after surgery. Challenges associated with eating and uncontrolled diarrhea were reported to be the most demanding symptoms, limiting social activities and hindering the patients' attempts to resume their former identity. In many cases, the patients were dependent on their spouses with regard to the activities of daily life. Being surgically treated for a cancer with a potentially poor prognosis was experienced as akin to living in limbo. Uncertainty regarding their future health posed challenges for the patients in terms of their vocational life and general life planning.
CONCLUSION: Patients may require additional support in coping with their new life situation following surgery for esophageal cancer. The heavy burden on a patient spouse should also be recognized from the time of hospital discharge. Moreover, patients may benefit from closer follow-up by healthcare providers, including support groups to help cope with insecurity and fear of relapse.
FIELD: medicinal microbiology. SUBSTANCE: invention relates to new method of preparing the preparation for indication of diphtheria toxin on liquid nutrient medium. Method is realized in 0.05 M glycine-saline buffer solution, pH = 8.2-8.25, by immobilization of gamma-globulin showing immunity to diphtheria pathogen on surface of polystyrene latex particles activated with methacrylic acid and zinc methacrylate in the presence of bovine serum albumin, polyethylene glycol and preserving agent. The used latex is a mixture of modified polystyrene latex at dispersity 0.20-0.25 mcm and 1.1-1.2 mcm. Components for preparing the preparation were taken at definite ratio. EFFECT: improved method of preparing.
OBJECTIVES: I. Determine the maximum tolerated dose (MTD) of pegylated-interferon alfa-2a in patients with advanced or metastatic renal cell carcinoma. II. Evaluate the safety profile of the MTD in this patient population. III. Determine the objective response rate, time to response, duration of response, time to progression, and survival rate in this patient population.

OUTLINE: This is a dose escalation, open label, multicenter study. Patients receive pegylated-interferon alfa-2a (PEG-IFN) subcutaneously once a week for 24 weeks. Dose escalation of PEG-IFN continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. After the MTD of PEG-IFN is determined, additional patients are treated at this dose level. These patients may continue treatment after the first 24 weeks for up to 1 year, in the absence of disease progression. Patients are followed for 4 weeks.

PROJECTED ACCRUAL: A total of 46-58 patients will be accrued for this study within 9 months.
Acupressure (complementary and integrative medicine method) Acupressure will be applied individually to the experimental group for 18-20 minutes three times a day for three menstrual cycles (approximately 3 months). Data collection forms will be applied 4 times in total, before the intervention, within 5 minutes after acupressure, at the end of Cycle 1 and cycle 2 (each cycle is 28 days).
Providers in the RIT group (n=30) will receive an 8-hour virtual workshop (2 half-days) on RIT implementation and caregiver coaching. Each provider will invite 2 families in their caseload to participate in the study. Providers will coach families in the use of RIT. One intervention session for each enrolled family will be videotaped and scored for RIT fidelity.
The COVID-19 case group is a random sample of individuals who are enrolled in KPCO's health plan who are "cases" or "likely cases". These individuals may have positive antibodies to COVID-19.
Forty one (41) patients with microscopically confirmed premalignant oral epithelial disease (epithelial dysplasia) will be enrolled in this trial at three clinical centers, i.e. the Ohio State University, University of North Carolina at Chapel Hill and University of Louisville. At all three institutions, half of the participants will randomly be assigned to the 10% FBR gel (0.5 gm four times daily for 3 months), while half will enter the placebo control arm.

In accordance with the established standard of care, all participants need to have biopsies taken of their suspicious oral lesions to establish the diagnosis (non research). Trial participants will have three total biopsies. Pretreatment biopsies will entail: 1) perilesional tissue and single saliva sample for FBR metabolic profiling studies (tissue and saliva will be obtained 15 minutes after a single 0.5 gm application of 10% FBR gel for metabolic profiling. Gel application and nonlesional biopsy will be obtained before incisional biopsy of lesional tissue), and 2) a hemisection of lesional tissue to establish a diagnosis and provide a pretreatment baseline for the experimental parameters. While the pretreatment biopsy includes removal of both perilesional and lesional tissue, there will only be one surgical wound as the perilesional tissue is contiguous with the lesional tissue. A final excisional biopsy of the treatment site including any remaining residual lesional tissue (excision of oral dysplastic lesions is consistent with current standards of care) will be obtained after 3 months of treatment. The experimental design permits each patient to serve as their own internal control. Briefly, these following parameters will be monitored in all participants (comparisons made relative to patient-matched pretreatment to posttreatment biopsies): 1) light microscopic diagnoses, 2) clinical appearances and lesional sizes, 3) microarray gene expression analyses, 4) microvascular densities of superficial connective tissues, 5) LOH indices at loci associated with tumor suppressor genes, 6) intraepithelial levels of COX-2 and iNOS protein (image analysis quantified immunohistochemistry), 7) comparison of FBR metabolic profiles relative to extent of chemopreventive efficacy noted.
OBJECTIVE: Wallerian degeneration (WD) of the middle cerebellar peduncles (MCPs) following pontine infarction is a rare secondary degenerative neurological condition. Due to its infrequency, there is limited research on its characteristics.
METHODS: This study aims to present three cases of WD of MCPs following pontine infarction and to analyze the prognosis, clinical manifestations, and neuroimaging features by amalgamating our cases with previously reported ones.
RESULTS: The cohort consisted of 25 cases, comprising 18 men and 7 women aged 29 to 77 years (mean age: 66.2 years). The majority of patients (94%) exhibit risk factors for cerebrovascular disease, with hypertension being the primary risk factor. Magnetic resonance imaging (MRI) can detect WD of MCPs within a range of 21 days to 12 months following pontine infarction. This degeneration is characterized by bilateral symmetric hyperintensities on T2/FLAIR-weighted images (WI) lesions in the MCPs. Moreover, restricted diffusion, with hyperintensity on diffusion-weighted imaging (DWI) and low apparent diffusion coefficient (ADC) signal intensity may be observed as early as 21 days after the infarction. Upon detection of WD, it was observed that 20 patients (80%) remained asymptomatic during subsequent clinic visits, while four (16%) experienced a worsening of pre-existing symptoms.
CONCLUSIONS: These findings underscore the importance of neurologists enhancing their understanding of this condition by gaining fresh insights into the neuroimaging characteristics, clinical manifestations, and prognosis of individuals with WD of bilateral MCPs.
Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.
MEDICINAL COMPOSITION AND METHOD OF MAKING SAME                       ABSTRACT          A drug delivery system for delivering a pharmaceutical to the brush layer of the small intestine for absorption through the brush layer and for direct passage into the thoracic duct without digestion or breaking up in the stomach and with neither interception by nor reaction with the bile salts of the digestive system.  The system involves the formation of an emulsion of oil globules predominantly less than about 1000 .ANG. in diameter in which the pharmaceutical is contained, either dissolved in the oil or dispersed therein in water solution, and the integrity of each globule is maintained by an encasing water layer firmly held in place by surface tension.  As a part of the system and to insure proper delivery and protection of the emulsion, e.g. for shelf life and delivery to the stomach, the emulsion is mixed with a water absorbent powder, such as dextran, and the powder is encapsulated in a conventional gelatin capsule.  The technique of making the emulsion, of forming a solid composition for filling the capsule, and the composite capsule itself are all disclosed, as well as the unique drug delivery system.